Repare Therapeutics Profit Margin

The latest profit margin for RPTX is 173.53% as of September 2025. That compares with -126.34% in the prior-year period — up 237.3% year over year. That is above the Healthcare sector average of 14.34%. Investors often review this figure alongside Repare Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RPTX's profit margin moved from -126.34% to 173.53% — a 237.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Repare Therapeutics's valuation or profitability profile.

Against Healthcare companies, RPTX currently prints 173.53% for profit margin, while the sector average sits near 14.34%. That is roughly 1109.7% above the sector mean. Large gaps often invite a closer look at Repare Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Repare Therapeutics converts resources into returns. At 173.53%, RPTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -126.34% in the prior-year period — up 237.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RPTX's profit margin (173.53%), review year-over-year change from -126.34%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.